Vonoprazan Fumarate

富马酸伏诺拉生

Report date: 2026/03/16 20:01:47
NMEFirst In ClassQIDP

Base Information

Drug NameVonoprazan Fumarate
Drug Alias NameVonoprazanum伏诺拉生沃偌拉赞Vonoprazan FumarateVonoprazan +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium-transporting ATPase inhibitors
TargetsPotassium-transporting ATPase
Therapy Area/IndicationsRejection of renal transplantationHelicobacter pylori infectionHeartburn +[18] 
Global Approved IndicationsHelicobacter pylori infectionHeartburnStomach Ulcer +[9] 
Approved Indications in ChinaEsophagitis, Peptic
Original Approved Country/TerritoryJapan
Original Approved Date2014/12/26
Country/TerritoryUnited StatesTaiwanPakistan +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co LtdSun Yat-Sen Memorial Hospital Of Sun Yat-Sen UniversityHumanis Saglık Anonim Sirketi +[12] 
Inactive CompaniesGenuine Research Center, EgyptTianjin Takeda Pharmaceuticals Co Ltd
Active IndicationsRejection of renal transplantationHelicobacter pylori infectionHeartburn +[18] 
Inactive IndicationsN/A

Other Information

ATC CodeA02BC08
Related LinksWikipediaDrugBankKEGG